Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1???50% advanced non small cell lung cancer.
Auteurs : Doubre, H ; Greillier, L ; Justeau, G ; Ricordel, C ; Swalduz, A ; Curcio, H & al (Guisier F)
